GAP43 and Alzheimer disease: Moreover, most recent studies have shown increased CSF levels of GAP-43 in different brain areas of patients with AD continuum, suggesting this protein as a reliable biomarker in the diagnosis and monitoring of patients with cognitive decline (9, 26).